Lidocaine (injection): Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 12: | Line 12: | ||
==Category== | ==Category== | ||
==FDA Package Insert== | ==FDA Package Insert<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION [ASTRAZENECA LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=723c8e7e-75eb-4119-4ab0-ab52955869f7#nlm34067-9 | publisher = | date = | accessdate = }}</ref>== | ||
'''| [[Lidocaine indications and usage|Indications and Usage]]''' | '''| [[Lidocaine indications and usage|Indications and Usage]]''' | ||
Revision as of 17:01, 10 March 2014
| Lidocaine |
|---|
| XYLOCAINE® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Lidocaine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
For patient information, click here. Synonyms / Brand Names:
Overview
Category
FDA Package Insert[1]
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages